BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/31/2015 10:55:00 AM | Browse: 407 | Download: 681
Publication Name World Journal of Neurology
Manuscript ID 14311
Country/Territory United States
2014-09-29 11:29
Peer-Review Started
2014-09-29 21:53
To Make the First Decision
2014-10-14 17:48
Return for Revision
2014-10-21 18:54
2014-10-22 09:45
Second Decision
2014-12-15 08:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-12-19 17:51
Articles in Press
2014-12-19 17:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-03-26 19:12
Publish the Manuscript Online
2015-03-31 10:53
ISSN 2218-6212 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research and Experimental
Manuscript Type Review
Article Title Targeting remyelination treatment for multiple sclerosis
Manuscript Source Invited Manuscript
All Author List Maheen Nadeem, Lindsay Sklover and Jacob A Sloane
Funding Agency and Grant Number
Corresponding author Jacob A Sloane, Director, Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Ks212, Boston, MA 02115, United States. jsloane@bidmc.harvard.edu
Keywords Multiple sclerosis; Myelin; Remyelination; Oligodendrocyte; Repurposing; Treatment
Core Tip Over the last several years numerous remyelination pathways important to multiple sclerosis (MS) have been identified, including those of LINGO-1, hyaluronan, Notch-1, retinoid X receptor receptor, and wnt/β-catenin. Newer discoveries include the pathways involving Chemokine (C-X-C Motif) ligand 12/C-X-C chemokine receptor type 4 and G protein-coupled receptor 17, and the involvement of Endothelin-1 in the Notch pathway. High-throughput screens have identified multiple antimuscarinic drugs with good remyelination. Also identified by screens, clemastine, with similar antimuscarinic but also antihistamine effects, may be useful in remyelination in MS. Drug repurposing, through screens or more serendipitously, has found that many drugs could enhance remyelination, including benztropine, clemastine, quetiapine, fasudil, olesoxime, and ibudilast, among others.
Publish Date 2015-03-31 10:53
Citation Nadeem M, Sklover L, Sloane JA. Targeting remyelination treatment for multiple sclerosis. World J Neurol 2015; 5(1): 5-16
Url http://www.wjgnet.com/2218-6212/full/v5/i1/5.htm
DOI http://dx.doi.org/10.5316/wjn.v5.i1.5
Manuscript File 14311-Review.doc
Answering Reviewers 14311-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form 14311-Conflict-of-interest statement.pdf
Copyright License Agreement 14311-Copyright assignment.pdf
Peer-review Report 14311-Peer review(s).pdf
Scientific Misconduct Check 14311-CrossCheck.jpg
Scientific Editor Work List 14311-Scientific editor work list.pdf